Moecklinghoff C - Search Results

1

When can HIV clinical trials detect treatment effects on drug resistance?

Hill AM, Moecklinghoff C, DeMasi R. Hill AM, et al. Among authors: moecklinghoff c. Int J STD AIDS. 2015 Mar;26(4):268-78. doi: 10.1177/0956462414536885. Epub 2014 May 29. Int J STD AIDS. 2015. PMID: 24874537 Review.

2

Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?

Girard PM, Nelson M, Mohammed P, Hill A, van Delft Y, Moecklinghoff C. Girard PM, et al. Among authors: moecklinghoff c. AIDS. 2013 Nov 13;27(17):2759-63. doi: 10.1097/01.aids.0000432458.98851.c1. AIDS. 2013. PMID: 23842127 Clinical Trial.

3

Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials.

Powderly W, Hill A, Moecklinghoff C. Powderly W, et al. Among authors: moecklinghoff c. HIV Clin Trials. 2014 May-Jun;15(3):79-86. doi: 10.1310/hct1503-79. HIV Clin Trials. 2014. PMID: 24947531 Review.

4

Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events.

Clumeck N, Hill A, Moecklinghoff C. Clumeck N, et al. Among authors: moecklinghoff c. AIDS Rev. 2014 Oct-Dec;16(4):236-45. AIDS Rev. 2014. PMID: 25350532 Review.

5

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.

Antinori A, Clarke A, Svedhem-Johansson V, Arribas JR, Arenas-Pinto A, Fehr J, Gerstoft J, Horban A, Clotet B, Ripamonti D, Girard PM, Hill AM, Moecklinghoff C. Antinori A, et al. Among authors: moecklinghoff c. AIDS. 2015 Sep 10;29(14):1811-20. doi: 10.1097/QAD.0000000000000778. AIDS. 2015. PMID: 26372387 Free article. Clinical Trial.

6

Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues.

Winston A, Moecklinghoff C, Hill A. Winston A, et al. Among authors: moecklinghoff c. Int J STD AIDS. 2012 Mar;23(3):225-6. doi: 10.1258/ijsa.2011.011330. Int J STD AIDS. 2012. PMID: 22581885 No abstract available.

7

Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*.

Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Stephan C, et al. Among authors: moecklinghoff c. HIV Med. 2013 May;14(5):284-92. doi: 10.1111/hiv.12004. Epub 2012 Nov 22. HIV Med. 2013. PMID: 23171153 Free article. Review.

8

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. Arribas JR, et al. Among authors: moecklinghoff c. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944. AIDS. 2010. PMID: 20010070 Clinical Trial.

9

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Pulido F, et al. Among authors: moecklinghoff c. Antivir Ther. 2011;16(1):59-65. doi: 10.3851/IMP1710. Antivir Ther. 2011. PMID: 21311109

10

Impact of hepatitis C co-infection on response to antiretroviral treatment.

Pulido F, Hill A, van Delft Y, Moecklinghoff C. Pulido F, et al. Among authors: moecklinghoff c. AIDS Rev. 2012 Apr-Jun;14(2):124-31. AIDS Rev. 2012. PMID: 22627608 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters